Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Recombinant Anti-Met/Epcam Bispecific Antibody Fragment: A Promising Novel Therapeutic Approach for Breast Cancer Treatment Publisher Pubmed



R Mirzaei ROYA ; M Azimi MOHAMMADREZA ; S Karimi SOROUSH ; Ms Karimi Mahshid SEYED ; Sam Aghel Seyed Ali MIR ; M Salehi MALIHE ; N Jalili NEDA ; F Yadegari FATEMEH ; L Farahmand LEILA
Authors

Source: Investigational New Drugs Published:2025


Abstract

Our study aims to target Met and EpCAM to inhibit angiogenesis in breast cancer, particularly triple-negative breast cancer (TNBC). We have developed a new bispecific antibody that targets both MET and EpCAM, which are commonly overexpressed in tumor cells. This antibody aims to reduce tumor cell proliferation and spread. After cloning and expressing the anti-Met/EPCAM sequence in Escherichia coli, we confirmed its accuracy through Western blot analysis. Flow cytometry indicated its binding activities to MET and EPCAM on MDA-MB-231 and MCF-7 cell lines. Our antibody showed anti-proliferative potential as indicated by apoptosis and MTT assay, leading to the inhibition of migration and invasion in breast cancer cell lines. After conducting a thorough analysis of cytokine production, we discovered that our bispecific antibody effectively influenced the levels of IL-8 and IL-6. These cytokines play crucial roles in angiogenesis and the progression of breast cancer. These findings indicate that our bispecific antibody holds promise as a potential therapy for triple-negative breast cancer. It has the potential to impede the formation of new blood vessels in tumors, thus restraining their growth and spread. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Dual in Vitro Invasion/Migration Suppressing and Tamoxifen Response Modulating Effects of a Recombinant Anti-Alcam Scfv on Breast Cancer Cells, Cell Biochemistry and Function (2020)
2. A Novel Adc Targeting Cell Surface Fibromodulin in a Mouse Model of Triple-Negative Breast Cancer, Breast Cancer (2022)
3. Antibody Based Epcam Targeted Therapy of Cancer, Review and Update, Current Cancer Drug Targets (2018)
Experts (# of related papers)
View all Related Experts
Fazel Shokri (2)
Saeid Amanpour (1)
Other Related Docs
4. Synthesis of the Scfv Fragment of Anti-Frizzled-7 Antibody and Evaluation of Its Effects on Triple-Negative Breast Cancer in Vitro Study, Clinical and Translational Oncology (2024)
5. Development of a Recombinant Anti-Vegfr2-Epcam Bispecific Antibody to Improve Antiangiogenic Efficiency, Experimental Cell Research (2021)
6. Production of Novel Recombinant Anti-Epcam Antibody As Targeted Therapy for Breast Cancer, International Immunopharmacology (2023)
7. Development of a Met-Targeted Single-Chain Antibody Fragment As an Anti-Oncogene Targeted Therapy for Breast Cancer, Investigational New Drugs (2023)
8. Anti-Neoplastic Effects of Aprotinin on Human Breast Cancer Cell Lines: In Vitro Study, Advances in Clinical and Experimental Medicine (2019)
9. Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer, Turk Onkoloji Dergisi (2020)
10. Nf-Κb As the Main Node of Resistance to Receptor Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer, Tumor Biology (2017)
11. The Effects of Metformin and Pcl-Sorafenib Nanoparticle Co-Treatment on Mcf-7 Cell Culture Model of Breast Cancer, Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
12. Evolutionary Hypothesis in Cell Cycle of Breast Cancer Patients: Mosaic Phases in Single Cancer Cells, Journal of Cancer Research Updates (2022)
13. Mir-483-3P Suppresses the Proliferation and Progression of Human Triple Negative Breast Cancer Cells by Targeting the Hdac8>Oncogene, Journal of Cellular Physiology (2020)
14. Bispecific Therapeutics: A State-Of-The-Art Review on the Combination of Immune Checkpoint ‎Inhibition With Costimulatory and Non-Checkpoint Targeted Therapy, Expert Opinion on Biological Therapy (2024)
15. Expression of Mirnas Targeting Mtor and S6k1 Genes of Mtor Signaling Pathway Including Mir-96, Mir-557, and Mir-3182 in Triple-Negative Breast Cancer, Applied Biochemistry and Biotechnology (2018)
16. Radiolabeled Her2-Targeted Molecular Probes in Breast Cancer Imaging: Current Knowledge and Future Prospective, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
17. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
18. In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex, Translational Oncology (2025)
19. Extracellular Nampt/Visfatin Induces Proliferation Through Erk1/2 and Akt and Inhibits Apoptosis in Breast Cancer Cells, Peptides (2017)
20. Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model, International Immunopharmacology (2023)